Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

597
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
597
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

970
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
970
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

845
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
845
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

749
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
749
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

753
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
753

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation and Exploratory Refinement of the HFA-ICOS Score for Cardiovascular Risk in Proteasome Inhibitor-Treated Multiple Myeloma: Single-Center Retrospective Study.

Cancers·2026
Same author

Frailty and Congestion in Patients with Heart Failure: Clinical Interaction and Prognostic Implications.

Journal of clinical medicine·2026
Same author

Low-dose Empagliflozin Does Not Modify Myocardial Energetics and Function in a Large-animal Model of Hibernating Myocardium.

Journal of cardiovascular translational research·2026
Same author

Circulating palmitoleic acid is associated with cerebral glucose metabolism in healthy middle-aged individuals: results from the Progression of Early Subclinical Atherosclerosis prospective cohort study.

The American journal of clinical nutrition·2026
Same author

Growing with the patient: toward a lifespan risk score for pediatric pulmonary hypertension.

Revista espanola de cardiologia (English ed.)·2026
Same author

Mapping Echocardiographic Practice in Emilia-Romagna: A Regional Healthcare Census.

Journal of clinical medicine·2026
Same journal

Sparganosis.

The New England journal of medicine·2026
Same journal

Caring for an Aging America - The Looming Crisis of the Long-Term-Care Workforce.

The New England journal of medicine·2026
Same journal

For Those Left Behind.

The New England journal of medicine·2026
Same journal

Colliding Forces - The Aging of the Baby Boom Generation and Contracting Nursing-Home Supply.

The New England journal of medicine·2026
Same journal

Mandated State-Level Surveillance of Assisted Reproductive Technology - An Emerging Threat in the United States.

The New England journal of medicine·2026
Same journal

Ebola at 50 - Lessons for Outbreak Response and Preparedness.

The New England journal of medicine·2026
See all related articles

Related Experiment Video

Updated: Sep 9, 2025

The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

22.1K

Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction.

Borja Ibanez1,2,3, Roberto Latini4, Xavier Rossello1,3,5,6

  • 1Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid.

The New England Journal of Medicine
|September 1, 2025
PubMed
Summary
This summary is machine-generated.

Beta-blocker therapy showed no significant benefit for patients after myocardial infarction with preserved ejection fraction. This study found no difference in death, reinfarction, or heart failure hospitalization rates.

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.6K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.4K

Related Experiment Videos

Last Updated: Sep 9, 2025

The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

22.1K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.6K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.4K

Area of Science:

  • Cardiology
  • Clinical Trials
  • Pharmacology

Background:

  • Current beta-blocker guidelines post-myocardial infarction (MI) are based on older trial data predating modern treatments.
  • Contemporary care includes routine reperfusion, invasive strategies, and advanced pharmacotherapy, necessitating updated evidence.
  • The role of beta-blockers in MI patients with preserved ejection fraction (LVEF > 40%) remains uncertain under current treatment paradigms.

Purpose of the Study:

  • To evaluate the efficacy of beta-blocker therapy versus no beta-blocker therapy in acute MI patients with LVEF > 40%.
  • To assess the impact of beta-blockers on major adverse cardiovascular events in this specific patient population.
  • To provide evidence-based recommendations for beta-blocker use in contemporary MI management.

Main Methods:

  • An open-label, randomized trial conducted in Spain and Italy.
  • 8438 patients with acute MI and LVEF > 40% were randomized to beta-blocker or no beta-blocker therapy.
  • Primary outcome: composite of all-cause death, reinfarction, or hospitalization for heart failure, with a median follow-up of 3.7 years.

Main Results:

  • No significant difference in the primary outcome between the beta-blocker group (22.5 events/1000 patient-years) and the no-beta-blocker group (21.7 events/1000 patient-years); hazard ratio (HR) 1.04, P=0.63.
  • Individual components of the primary outcome (all-cause death, reinfarction, heart failure hospitalization) also showed no significant between-group differences.
  • Safety outcomes did not reveal any apparent differences between the treatment groups.

Conclusions:

  • Beta-blocker therapy did not demonstrate a significant effect on the composite outcome of death, reinfarction, or heart failure hospitalization in patients post-MI with LVEF > 40% receiving invasive care.
  • Findings suggest current guideline recommendations for beta-blockers in this specific MI subgroup may need re-evaluation.
  • The study was funded by Centro Nacional de Investigaciones Cardiovasculares Carlos III and others; NCT03596385.